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Triple Inhaler Therapy in Adolescents and Adults with Moderate and Severe Persistent Asthma

ABSTRACT
Expert guidelines, metanalysis, and multiple randomized controlled trials have demonstrated the
effectiveness of long-acting inhaled antimuscarinic agents (LAMA) as an additive medication in
poorly controlled moderate and severe persistent asthma. LAMAs play an essential role in
blocking acetylcholine binding to muscarinic receptors and reducing bronchoconstriction and
mucous production. By adding this medication to other combination inhalers - long-acting betaagonists (LABA) and inhaled corticosteroids (ICS), patients can utilize a triple inhaler to
improve FEV1 values and decrease exacerbations. Current treatment guidelines allow clinicians
to develop more personalized treatment plans for their asthmatic patients.
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INTRODUCTION
According to national CDC statistics,1 asthma in adolescents and adults continues to be a
common disease with the highest prevalence rates in females, non-Hispanic black and American
Indians / native Alaskans, and individuals 100% below the national poverty threshold. Data
from 20191 estimates the frequency of emergency medical visits at 41.8%, and inpatient
admissions at 4.1% in individuals seen with the diagnosis of asthma in the past twelve months.
Moderate and severe persistent asthma accounts for 5-10% of the cases and attributes to more
than 60% of the cost of healthcare.2 Suruki and colleagues3 defined poorly controlled asthma as
those requiring Steps 4 and 5 medication treatment, as well as frequent exacerbations, and high

asthma control test scores (ACT) or asthma control questionnaire (ACQ). The frequency of
exacerbations doubles from patients on step 1 treatment as compared to step 5 treatment.3
Patients who have comorbidities are the ones who have a lower socioeconomic status.2
Eventually, patients have airway remodeling with features consistent with asthma and chronic
obstructive lung disease (COPD) overlap syndrome.
Global initiative for asthma (GINA)4 has recommended the addition of LAMAs to be
added to long-acting beta-agonists (LABA) and inhaled corticosteroids (ICS) for steps 5 who
have poorly controlled moderate and severe persistent asthma. LAMAs play an important role in
blocking the binding of acetylcholine to muscarinic receptors, which are released during asthma
exacerbations.5,6 Activation of these receptors leads to additional bronchoconstriction and mucus
production. Many clinicians are familiar with the use of short-acting antimuscarinic agents
during acute asthma exacerbation but may be unaware of LAMAs use in managing uncontrolled
moderate and severe persistent asthma. This article aims to provide a clinical overview of
asthma phenotypes with a focus on novel bronchodilator management strategies.

Significance to Primary Care
Asthma continues to be a very common diagnosis1 that is managed in the outpatient
setting, with frequent hospitalization for poorly controlled, and non-compliant patients.
According to Soriano et al,7 the overall prevalence of asthma has increased from 1990 to 2015 by
12.6%, and ranked 23rd for disease burden, which is measured by disability-adjusted life years
(DALYs). Murrison and colleagues8 report multiple indoor and outdoor environmental
pollutants increase the burden of allergies, which is a factor in these increasing prevalence rates
of asthma. Another important issue with asthma is medication compliance, and the cost of

treatment. Finding an effective cost-effective therapy, which is user-friendly to utilize is of
utmost importance. According to Jansen et al,9 medication adherence for asthma patients is as
low as 22.2% in the United States. Adherence can be further broken down by poor
understanding of inhaler frequency (once vs twice /day dosing), poor technique, and deliberate
non-compliance. The healthcare costs of patients with asthma are 3.5 times greater than patients
without asthma.9 The use of triple therapy (ICS/LABA/ LAMA) in moderate and severe poorly
controlled therapy helps ease the complexity of the treatment plan by having just one inhaler and
has demonstrated improved FEV1 levels and decreased hospitalizations.10,11 Augusti et al12 noted
the cost of triple inhalers may be more expensive, but the benefit of reduced hospitalizations
outweighs the cost to the healthcare system.
Long-term controllers of asthma are broken down into three categories; Inhaled
Corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting antimuscarinic agents
(LAMA). The major role of these medications is to reduce airway inflammation, and recent
literature supports the usefulness of measuring fractionated exhaled nitric oxide (FeNO) levels to
be a predictor of airway inflammation and responsiveness to the effects of these medications.13
FeNO levels are increased in type 2 inflammation which occurs by activating cytokines, and
excessive production of FeNO from epithelium cells.14 FeNO Levels > >50 ppb in adults are
considered high, and 25 to 50 ppb are considered intermediate.13 Monitoring FeNO is an
important measurement in patients, to evaluate change in inflammation. Currently, there are
several handheld devices on the market that can be utilized to measure this inflammatory marker.

CLINICAL PRESENTATION

Clinical signs and symptoms of asthma include shortness of breath, cough, and wheezing.
Symptoms may be triggered by exercise or exposure to allergens, and the cough is often worse at
night or early morning. Once a clinician suspects asthma, pulmonary function tests (PFT) are
generally performed to help confirm the diagnosis. PFTs can demonstrate an obstructive pattern
- decreased FEV1, and FEV1/FVC ratio < 0.7-.85 % of predicted value, and an improvement with
post-bronchodilator therapy or improvement at 4 weeks of anti-inflammatory treatment of an
FEV1 by 12% of predicted value and 200ml.4

ONGOING CLINICAL ASSESSMENT
Once a diagnosis of asthma is established, patients should be reassessed utilizing a
combination of both subjective and objective measures. The asthma control test (ACT) and
asthma control questionnaire (ACQ) are useful validated measures of subjective asthma
symptoms and control. Home peak flow trends and in-office comparisons can also be used as
objective measures. PFTs should also be performed on at least a yearly basis to evaluate for
improvement and to confirm if non-reversible disease has occurred. For patients with poorly
controlled moderate and persistent asthma, additional testing is warranted and helps distinguish
specific phenotypes which guide further treatments. Levels of FeNO, serum IgE, sputum, and
blood eosinophil can be used to demonstrate increased type 2 inflammation within the airways.15
Allergy testing with RAST or skin prick testing can further identify specific allergens which may
include food, animal, dust, pollen, and insect allergies. The results of this additional testing will
designate patients into specific phenotypes (Figure 1) and help customize appropriate treatment.

Figure 1

Phenotype

Biomarker

Treatment Options

Allergic asthma

Elevated IgE

Anti-IgE (omalizumab)

Eosinophilic asthma

Elevated eosinophils (blood >= 300 uL,
sputum >= 3%)

Anti-IL-5 treatment
(mepolizumab, reslizumab,
benralizumab)
Anti-IL-4 and IL-3 (dupilumab)

Non-eosinophil asthma

Absence of increased eosinophils, and
normal IgE levels

Long-acting bronchodilators
(LAMA/LABA/ICS)

Elevated FeNO levels demonstrates ongoing airway inflammation and signifies the need
for additional anti-inflammatory medications and referral to an asthma specialist. Elevation in
IgE is categorized as allergic asthma, and signifies the need for further allergy testing. Elevation
in eosinophils in the sputum or blood is categorized as eosinophil asthma, and lack of eosinophils
with normal IgE as non-eosinophilic asthma.

ASTHMA TREATMENT
Asthma treatment has changed significantly over the past 5 years, with more customized
management based on ongoing inflammation, poor control, phenotyping, and advances in
therapy. GINA often releases new recommendations yearly and has updated its stepped

treatment approach in 2022 (Box 3-5a).16

For steps 1 and 2 treatment in the mild intermittent asthma classification, the use of an
ICS/LABA in the form of ICS-formoterol is indicated.4,16 The addition of a LAMA to all patients
in step 5 and as an alternative treatment in step 4 is in alignment with severe persistent and
moderate persistent asthma respectively. The use of these triple inhalers (ICS/LABA/LAMA)
has simplified inhaler administration with this use of one controller inhaler. In addition, more
customized treatment plans for moderate and severe asthma are based on phenotyping.16

DISCUSSION
Early use of medications that reduce that reduces inflammation is essential to the control
of asthma. A randomized controlled study by O’Bryne and colleagues17 demonstrated the
benefit of improved symptom control and reduction in exacerbation which lead to the changes in
the GINA step 1 guideline.4 Additionally, recognizing the signs and symptoms of poorly

controlled asthma warrants additional measures to look for airway inflammation as measured by
elevated FeNO levels, in addition to phenotyping to further customize therapy.13,18
The addition of LAMAs to uncontrolled moderate and severe persistent asthma had been
proven to significantly reduce exacerbations and improve FEV1 values over time with their
use.10,12,19 Kim and associates19 reported a reduction of severe asthma exacerbations from 27.4%
with ICS/LAMA to 22.7% with ICS/LABA/LAMA use, and an improvement of FEV1 from 37%
to 47% of patients using ICS/LABA vs ICS/LABA/LAMA respectively. Triple inhalers
(ICS/LABA/LAMA) allow patients to have the benefit of all three controller medications in one
and have the benefit of better compliance.19,20 Singh et al21 noted that patients with more
reversible disease in the TRIMARAN and TRIGGER double-blinded randomized control study,
had better efficacy with triple inhaler use, than those on ICS/LABA.
As reported by Kim et al19 self-reporting tests such as ACT and ACG showed an
improvement in the patient's asthma symptoms with the addition of the triple inhaler, but didn’t
show a significant improvement in quality of life measures. There were no significant
differences in mortality with the addition of LAMA with these triple inhalers. The most
commonly reported side effects were dry mouth and dysphonia.

Conclusion
Asthma care continues to have new advances, with the focus being on more individualized
treatments. Preventing airway inflammation is of utmost importance, and newer treatment
modalities aim to do this. GINA has recommended the addition of LAMAs to poorly controlled
moderate and persistent asthma. The use of a triple inhaler enhances compliance and has been
shown to cause improvement in symptoms, improved FEV1, and reduction in asthma

exacerbations with minimal side effects. Additional concerns about cost need to be addressed
since some insurances are still not including triple inhalers on their formulary.

References
1. Most Recent National Asthma Data | CDC. Published May 26, 2022. Accessed November 15,
2022. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
2. O’Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and
mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54(1):1900491.
doi:10.1183/13993003.00491-2019
3. Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and
healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med.
2017;17(1):74. doi:10.1186/s12890-017-0409-3
4. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021:
executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730.
doi:10.1183/13993003.02730-2021
5. Muiser S, Gosens R, van den Berge M, Kerstjens HAM. Understanding the role of long-acting
muscarinic antagonists in asthma treatment. Ann Allergy Asthma Immunol. 2022;128(4):352360. doi:10.1016/j.anai.2021.12.020
6. Parkey SM, Mospan CMP. Is there a role for inhaled anticholinergic therapy in asthma
management?. [Miscellaneous Article]. JAAPA. 2017;30(9):9-10.
doi:10.1097/01.JAA.0000522144.52305.e3
7. Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence,
disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary
disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study
2015. Lancet Respir Med. 2017;5(9):691-706. doi:10.1016/S2213-2600(17)30293-X
8. Murrison LB, Brandt EB, Myers JB, Hershey GKK. Environmental exposures and
mechanisms in allergy and asthma development. J Clin Invest. 2019;129(4):1504-1515.
doi:10.1172/JCI124612
9. Jansen EM, van de Hei SJ, Dierick BJH, Kerstjens HAM, Kocks JWH, van Boven JFM.
Global burden of medication non-adherence in chronic obstructive pulmonary disease
(COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. J
Thorac Dis. 2021;13(6):3846-3864. doi:10.21037/jtd-20-2360
10.Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled
asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised,
controlled phase 3 trials. The Lancet. 2019;394(10210):1737-1749. doi:10.1016/S01406736(19)32215-9
11.Nakamura Y, Hozawa S, Sagara H, et al. Efficacy and safety of once-daily, single-inhaler
fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese
patients with inadequately controlled asthma: the CAPTAIN study. Curr Med Res Opin.
2021;37(9):1657-1665. doi:10.1080/03007995.2021.1944849
12.Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in
asthma: Systematic review and practice implications. Allergy. 2022;77(4):1105-1113.
doi:10.1111/all.15076
13.Loewenthal L, Menzies-Gow A. FeNO in Asthma. Semin Respir Crit Care Med. Published
online March 4, 2022. doi:10.1055/s-0042-1743290
14.Ulrik CS, Lange P, Hilberg O. Fractional exhaled nitric oxide as a determinant for the clinical
course of asthma: a systematic review. Eur Clin Respir J. 2021;8(1):1891725.
doi:10.1080/20018525.2021.1891725
15.Schoettler N, Strek ME. Recent Advances in Severe Asthma: From Phenotypes to

Personalized Medicine. Chest. 2020;157(3):516-528. doi:10.1016/j.chest.2019.10.009
16.Global Initiative for Asthma. Global Initiative for Asthma - GINA. Accessed October 27,
2022. https://ginasthma.org/
17.O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide–Formoterol
as Needed in Mild Asthma. N Engl J Med. 2018;378(20):1865-1876.
doi:10.1056/NEJMoa1715274
18.Gill R. Fractional Exhaled Nitric Oxide (FENO) testing for the primary care practitioner.
2022;4:17.
19.Kim LHY, Saleh C, Whalen-Browne A, O’Byrne PM, Chu DK. Triple vs Dual Inhaler
Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and
Meta-analysis. JAMA. 2021;325(24):2466-2479. doi:10.1001/jama.2021.7872
20.Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone–
indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–
salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, doubleblind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000-1012.
doi:10.1016/S2213-2600(20)30190-9
21.Singh D, Virchow JC, Canonica GW, et al. Determinants of response to inhaled extrafine
triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res.
2020;21(1):285. doi:10.1186/s12931-020-01558-y

Key Points
Addition of LAMA in a triple inhaler should be considered in poorly controlled moderate and
severe persistent asthma
FeNO testing will determine the effectiveness of anti-inflammatory medications
LAMA use could improve symptoms, improve FEV1, and reduce exacerbations of asthma

